Reports
Global BREO Ellipta Drugs Market Share, Size, Growth, Report, Analysis: By Indication Type: Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Chronic Bronchitis, Asthma, Others; By Mode of Administration: Dry Powder Inhaler, Respimat Soft Mist Inhaler, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
BREO Ellipta Drugs Market Outlook
The global BREO ellipta drugs market is driven by the growing chronic obstructive pulmonary disease drugs market, which is likely to grow at a rate of 4.5% during the forecast period of 2023-2031. The prevalence of these respiratory disease is expected to rise significantly over the coming years due to rising pollution levels, along with other factors.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
BREO Ellipta Drugs Market: Introduction and Insights
The pharmaceutical market for asthma and other respiratory diseases has increased by manifolds in the past few years due to the poor air quality across majority of the region. The BREO ellipta drug is one such drug and is approved for asthma patients over the age of 18 years. It is a prescription only powder inhaler which is used for one inhalation for one time each day to ease and control the symptoms of asthma to a significant extent. It helps the breathing process and controls wheezing.
The drug contains vilanterol, which is a long-acting beta2-adrenergic agonist (LABA) medicine and can be fatal if used alone. This is why BREO contains a combination of inhaled corticosteroid (ICS) called fluticasone and a long-acting beta2-adrenergic agonist, which reduces the risk of any fatal effects. Fluticasone helps in reducing the swelling in the lungs. On the other hand, Vilanterol aids in the relaxation of muscles around the airways and can ease the process of breathing. While the drug is extremely effective if used regularly as per the doctor’s prescription, it needs to be used responsibly and not for sudden asthma attacks as it does not work as fast as a rescue inhaler.
Along with asthma patients, the BREO ellipta drug is also used in patients suffering from any other lung diseases like chronic obstructive pulmonary diseases (COPD) like chronic bronchitis and emphysema.
The drug also poses the threats of multiple side-effects. Some of these potential side-effects include choking, wheezing, fast or pounding heartbeats or any sort of pounding in the neck or ears, sores or white patches in the mouth and throat, pain when swallowing, fever, chills, cough with yellow or green mucus, blurred vision, eye pain, or seeing halos around lights, high blood sugar, increased thirst and urination, frequent cramps, constipation, muscle weakness or limp feeling, signs of a hormonal disorders.
BREO Ellipta Drugs Market Segmentations
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market can be divided on the basis of indication type, mode of administration, distribution channel, and major regions.
Market Breakup by Indication Type
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Chronic Bronchitis
- Asthma
- Others
Market Breakup by Mode of Administration
- Dry Powder Inhaler
- Respimat Soft Mist Inhaler
- Pressurized Metered Dose Inhaler
- Nebulizers
- Others
Market Breakup by Distribution Channel
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
BREO Ellipta Drugs Market Scenario and Epidemiology of Respiratory Disorders
The BREO Ellipta drugs market has been on a rise, especially since the prevalence of respiratory disease increased since the coronavirus pandemic. It triggered the respiratory issues amongst the people across the globe. The drug is still not affordable for a lot of people as most of the patients are from the rural areas. COPD affects more than 300 million people globally and about 3 million of these people are affected due to air pollution in households and more than 14% of these cases are caused due to the occupational environment and exposures. While most of the patients belong to rural areas, urban areas also witness significant exposure to COPD. In terms of smoking habit, more than 40% of the patients are people who have never smoked in their life.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the BREO Ellipta drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- GSK plc
- Akros Pharma Inc
- Sun Pharmaceutical Industries Ltd
- Gilead Sciences, Inc.
- Abbott
- Genosco Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication Type |
|
| Breakup by Mode of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Breo Ellipta Drugs Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Breo Ellipta Drugs Market
6.1 Global Breo Ellipta Drugs Market Overview
6.2 Global Breo Ellipta Drugs Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Breo Ellipta Drugs Market Historical Value (2016-2022)
6.2.1.2 Global Breo Ellipta Drugs Market Forecast Value (2023-2031)
6.3 Global Breo Ellipta Drugs Market by Indication Type
6.3.1 Market Overview
6.3.1.1 Chronic Obstructive Pulmonary Disease (COPD)
6.3.1.2 Cystic Fibrosis
6.3.1.3 Chronic Bronchitis
6.3.1.4 Asthma
6.3.1.5 Others
6.4 Global Breo Ellipta Drugs Market by Mode of Administration
6.4.1 Market Overview
6.4.1.1 Dry Powder Inhaler
6.4.1.2 Respimat Soft Mist Inhaler
6.4.1.3 Pressurized Metered Dose Inhaler
6.4.1.4 Nebulizers
6.4.1.5 Others
6.5 Global Breo Ellipta Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.1.1 Hospital Based Pharmacies
6.5.1.2 Online Pharmacies
6.5.1.3 Retail Pharmacies
6.6 Global Breo Ellipta Drugs Market by Region
6.6.1 Market Overview
6.6.1.1 North America
6.6.1.1.1 Historical Trend (2016-2022)
6.6.1.1.2 Forecast Trend (2023-2031)
6.6.1.2 Europe
6.6.1.2.1 Historical Trend (2016-2022)
6.6.1.2.2 Forecast Trend (2023-2031)
6.6.1.3 Asia Pacific
6.6.1.3.1 Historical Trend (2016-2022)
6.6.1.3.2 Forecast Trend (2023-2031)
6.6.1.4 Latin America
6.6.1.4.1 Historical Trend (2016-2022)
6.6.1.4.2 Forecast Trend (2023-2031)
6.6.1.5 Middle East and Africa
6.6.1.5.1 Historical Trend (2016-2022)
6.6.1.5.2 Forecast Trend (2023-2031)
7 North America Breo Ellipta Drugs Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2 Canada
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8 Europe Breo Ellipta Drugs Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2 Germany
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 France
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 Italy
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Breo Ellipta Drugs Market
9.1 China
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2 Japan
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 India
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 ASEAN
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5 Australia
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Breo Ellipta Drugs Market
10.1 Brazil
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2 Argentina
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Mexico
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Breo Ellipta Drugs Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Nigeria
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
12.4.1.1 US FDA
12.4.1.2 EU EMA
12.4.1.3 INDIA CDSCO
12.4.1.4 JAPAN PMDA
12.4.1.5 Others
13 Challenges & Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Breo Ellipta Drugs Market Dynamics
14.1 Market Drivers and Constraints
14.2 Drug Adoption Parameters
14.3 SWOT Analysis
14.4 Porter Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Industry Events, Initiatives, and Trends
14.8 Value Chain Analysis
15 Supplier Landscape
15.1 GSK plc
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Akros Pharma Inc
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Sun Pharmaceutical Industries Ltd
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Gilead Sciences, Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Abbott
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Genosco Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
16 Recommendations and Discussion
17 Pricing Models and Strategies (Additional Insight)
17.1 Cost Model
17.1.1 Manufacturing Cost Analysis
17.1.2 Procurement Cost Analysis
17.2 Pricing Strategies
17.2.1 Competitor Pricing Analysis
17.2.2 Key Assessment of Product Attributes
17.2.3 Pricing Benchmark
18 Global Breo Ellipta Drugs Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is likely to be driven by the rising chronic obstructive pulmonary disease drugs market, which is expected to grow at a CAGR of 4.5% during the forecast period of 2023-2031.
The growth of the market is primarily driven by the rising respiratory diseases like asthma and COPD, among others.
The key trends in the market include the rising cases of asthma induced by the rising pollution across the globe.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
The segmentation on the basis of indication type includes chronic obstructive pulmonary disease (COPD), cystic fibrosis, chronic bronchitis, and asthma, among others.
The modes of administration include dry powder inhaler, Respimat soft mist inhaler, pressurized metered dose inhaler, and nebulizers, among others.
The distribution channels include hospital-based pharmacies, online pharmacies, and retail pharmacies.
The key companies involved in the market are GSK plc, Akros Pharma Inc, Sun Pharmaceutical Industries Ltd, Gilead Sciences, Inc., Abbott, and Genosco Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER